Editas Medicine Reports on Recent Progress and 2017 Goals at J.P. Morgan Healthcare Conference
January 09 2017 - 8:00AM
- Company Achieves In Vivo
Proof-of-Editing in the Retina of Non-Human
Primates -
In a presentation to investors on Wednesday, January 11, 2017 at
11:30am (PST) at the 35th Annual J.P. Morgan Healthcare Conference,
Editas Medicine, Inc. (NASDAQ:EDIT) President and CEO Katrine
Bosley will outline the Company’s progress on developing medicines
and building the leading genomic medicine company. In her
remarks, Ms. Bosley will discuss several components of the
Company’s growth, including:
- Driving Editas Medicine’s unparalleled platform for
genome editing medicines. As the only company with
access to the CRISPR genome editing systems Cas9, advanced forms of
Cas9, and the novel Cpf1 genome editing system, Editas Medicine has
the potential to treat the broadest range of diseases through
efficient editing of nearly any genetic target.
- Advancing a pipeline strategy to enable successful
product development in the years ahead. For Editas
Medicine’s LCA10 program, this includes achieving the first in vivo
proof-of-editing in the retina of non-human primates, as well as
the Company’s goal to submit an IND for the LCA10 program by the
end of 2017. In addition, Ms. Bosley will discuss recent progress
in achieving consistent, durable editing in hematopoietic stem
cells and high efficiency editing of CAR-T cells.
- Building the business for the long term by assembling
the capabilities to fully develop and commercialize important
medicines. This includes aggressively developing
valuable partnerships, robust financial resources, an unmatched
patent position, and an outstanding team and culture to drive
Editas Medicine’s bold vision for years to come.
“We had a very strong 2016 that lays the important groundwork to
make 2017 a transformative year for Editas Medicine,” said Ms.
Bosley. “We are focused on driving our unparalleled platform
and executing our pipeline strategy while building the company into
the genomic medicine leader. At Editas Medicine, we have a
bold vision and are excited about unlocking the power of CRISPR to
design and develop genome editing therapies for patients suffering
from genetically-defined and genetically-treatable diseases.”
In addition, Ms. Bosley will outline the Company’s 2017 goals,
including driving the following critical initiatives:
- Submitting an IND for the LCA10 program by year-end 2017;
- Initiating an LCA10 clinical natural history study in
mid-2017;
- Achieving preclinical proof-of-concept for additional
programs;
- Establishing additional alliances aligned with the Company’s
business development strategy; and
- Continuing to build an outstanding organization and
culture.
About Editas Medicine Editas Medicine is a
leading genome editing company dedicated to treating patients with
genetically-defined diseases by correcting their disease-causing
genes. The Company was founded by world leaders in genome editing,
and its mission is to translate the promise of genome editing
science into a broad class of transformative genomic medicines to
benefit the greatest number of patients.
Forward-Looking Statements This press
release contains forward-looking statements and information within
the meaning of the Private Securities Litigation Reform Act of
1995. The words "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "plan," "potential,"
"predict," "project," "target," "should," "would," and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Forward-looking statements in this press release
include statements regarding the Company’s goals of submitting of
an IND for the LCA10 program by year-end 2017, initiating an LCA10
natural history study in mid-2017, achieving preclinical
proof-of-concept for additional programs and establishing
alliances. The Company may not actually achieve the plans,
intentions, or expectations disclosed in these forward-looking
statements, and you should not place undue reliance on these
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
these forward-looking statements as a result of various factors,
including: uncertainties inherent in the initiation and completion
of preclinical studies and clinical trials and clinical development
of the Company's product candidates; availability and timing of
results from preclinical studies and clinical trials; whether
interim results from a clinical trial will be predictive of the
final results of the trial or the results of future trials;
expectations for regulatory approvals to conduct trials or to
market products and availability of funding sufficient for the
Company's foreseeable and unforeseeable operating expenses and
capital expenditure requirements. These and other risks are
described in greater detail under the caption "Risk Factors"
included in the Company's most recent Quarterly Report on Form
10-Q, which is on file with the Securities and Exchange Commission,
and in other filings that the Company may make with the Securities
and Exchange Commission in the future. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and the Company expressly disclaims any obligation to
update any forward-looking statements, whether as a result of new
information, future events or otherwise.
Editas Media Contact
Dan Budwick
Pure Communications, Inc.
(973) 271-6085
dan@purecommunicationsinc.com
Editas Investor Contact
Mark Mullikin
Editas Medicine, Inc.
(617) 401-9083
mark.mullikin@editasmed.com
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Apr 2023 to Apr 2024